Compare AdaptHealth Corp (AHCO) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AdaptHealth Corp vs Bristol-Myers Squibb Co — how do they compare? AdaptHealth Corp trades at $5.75 (market cap $753.09M), while Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 172.5× AdaptHealth Corp's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | BMY | |
|---|---|---|
Market Cap | $753.09M | $129.94B |
Sector | Health | Health |
52-Week High | $13.38 | $65.89 |
52-Week Low | $5.22 | $42.60 |
Enterprise Value | $2.77B | $163.92B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $5.77, up 10.54% today but remains under significant pressure following recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal revenue growth but negative profitability margins. Recent news highlights multiple securities fraud investigations and a strategic shift through the sale of its diabetes unit to focus on sleep and respiratory care.
Despite 75% analyst buy ratings and an $11 consensus price target suggesting substantial upside, immediate risks are elevated. The company faces execution challenges with fixed-price contracts, ongoing legal scrutiny, and consecutive earnings misses. Investors must weigh the potential recovery against substantial operational and legal headwinds.
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AdaptHealth Corp
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
